Drugs / Degarelix
Degarelix
also known as
Firmagon · Degarelix acetate · Degarelix (as acetate) · Degarelix (Firmagon) · Degarelix accord · Degarelix acetate hydrate · Degarelix acetate, FE200486 · FE-200486 · +2 more
Other / unclassified targets GNRHR, TMPRSS2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Firmagon | — | 2009-02-17 | europa.eu ↗ |
| Approved | US (FDA) | FIRMAGON | — | 2008-12-24 | fda.gov ↗ |
Trials 91 · started per year
today
US approved 2008
EU approved 2009
2
3
1
2
2
2
4
2
8
5
5
10
5
3
4
3
7
2
2
5
1
1
3
4
1
3
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03358563 | Jan 2018 → Aug 2021 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 0 | NCT01852864 | Jul 2011 → Jul 2015 | prostate cancer | University of Cambridge | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT05839119 | Oct 2023 → Jul 2025 | infiltrating bladder urothelial carcinoma | Brown University | Terminated | No outcome recorded |
| Phase 1 | NCT05917860 | Jul 2023 → Jan 2026 overdue | prostate carcinoma | Turku University Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02324998 | Dec 2016 → May 2019 | prostate cancer | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT02468284 | Jul 2015 → Oct 2016 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06066437 | Mar 2024 → Dec 2026 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06218667 | Jan 2024 → Jan 2027 | prostate cancer | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01696877 | Jan 2013 → Aug 2017 | adenocarcinoma in situ | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 243 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT07801664 | Aug 2026 → Aug 2028 expected | prostate cancer | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT07455903 | Apr 2026 → Oct 2029 expected | prostate carcinoma | Baptist Health South Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT07335796 | Jan 2026 → Jan 2030 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07313241 | Nov 2025 → Nov 2030 expected | prostate cancer | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04176081 | Jul 2024 → Dec 2028 expected | prostate cancer | University Health Network, Toronto | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06397703 | Apr 2024 → Apr 2030 expected | prostate cancer | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT05501704 | Oct 2023 → Apr 2027 expected | hormone receptor-positive breast cancer, male breast carcinoma | Jose Pablo Leone | Recruiting | No outcome recorded |
| Phase 2 | NCT04585932 | Nov 2020 → Jan 2021 | metastatic prostate carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT04391556 | Sep 2020 → May 2023 | prostate adenocarcinoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT04397718 | Jul 2020 → Jun 2021 | COVID-19 | VA Office of Research and Development | Completed | Missed primary |
| Phase 2 | NCT04182594 | Jan 2020 → Jan 2023 | prostate cancer | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03947151 | Nov 2019 → Mar 2022 | invasive ductal breast carcinoma | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT03361735 | Aug 2018 → Mar 2024 overdue | prostate adenocarcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02972060 | Dec 2017 → Jan 2023 overdue | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02849990 | Mar 2017 → Dec 2018 | prostate adenocarcinoma | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT03069937 | Mar 2017 → Mar 2021 | prostate adenocarcinoma | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT02494713 | Oct 2015 → Sep 2017 | prostate cancer | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02159690 | Sep 2014 → Jan 2015 | prostate cancer | Kenneth Pienta, MD | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT02005887 | Feb 2014 → Aug 2017 | invasive breast carcinoma | ETOP IBCSG Partners Foundation | Completed | Met primary |
| Phase 2 | NCT02020070 | Dec 2013 → Jun 2026 | metastatic prostate carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01751451 | Dec 2012 → Sep 2020 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01746849 | Dec 2012 → Dec 2026 expected | leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01994239 | Dec 2012 → Mar 2022 overdue | prostate adenocarcinoma | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01630967 | Aug 2012 → Dec 2013 | prostate neoplasm | British Columbia Cancer Agency | Withdrawn | No outcome recorded |
| Phase 2 | NCT01674270 | Aug 2012 → Dec 2014 | prostate cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT01446991 | Apr 2012 → Feb 2017 | prostate cancer | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 2 | NCT01491971 | Jan → Nov 2012 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01377389 | Jun 2011 → Apr 2017 | prostate cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01545882 | May → Oct 2011 | prostate cancer | Ottawa Hospital Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT01261572 | Oct 2010 → Apr 2012 | prostate neoplasm | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00947882 | Aug 2009 → Mar 2011 | — | Ferring Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT00738673 | Jul 2008 → Dec 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00527488 | Oct 2007 → Mar 2009 | benign prostatic hyperplasia | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00468286 | May 2007 → Aug 2008 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00434122 | Mar → Dec 2007 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00819156 | Feb 2004 → Jun 2005 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00116779 | Feb 2004 → Aug 2005 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00215657 | Mar 2003 → Mar 2006 | prostate cancer | Ferring Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00818623 | Nov 2002 → Oct 2004 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00117312 | Oct 2002 → Nov 2005 | prostate cancer | Ferring Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00117949 | Apr 2002 → Jan 2004 | prostate cancer | Ferring Pharmaceuticals | Completed | Mixed |
| Phase 2 | NCT00245466 | Oct 2001 → Mar 2006 | prostate cancer | Ferring Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00819247 | Mar 2001 → May 2002 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT00268892 | Jan 2006 → Sep 2009 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT00117286 | Mar 2005 → Sep 2009 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT00215683 | Feb 2005 → Oct 2009 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 325 trials · 5 met primary · 2 missed | ||||||
| Phase 3 | NCT02799706 | Sep 2017 → Aug 2023 overdue | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03056638 | Mar 2017 → Aug 2023 | prostate cancer | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02663908 | Apr 2016 → Mar 2021 | prostate cancer | Ferring Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02526784 | Dec 2015 → May 2017 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02015871 | Jan 2014 → Aug 2017 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01964170 | Aug 2013 → Jun 2015 | prostate cancer | Astellas Pharma Inc | Completed | Met primary |
| Phase 3 | NCT01744366 | Jan 2013 → May 2015 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01712763 | Nov 2012 → Mar 2016 | endometriosis | Centre for Endocrinology and Reproductive Medicine, Italy | Completed | No outcome recorded |
| Phase 3 | NCT01709942 | Nov 2012 → Dec 2015 | infertility disorder, ovarian hyperstimulation syndrome, polycystic ovary syndrome | Centre for Endocrinology and Reproductive Medicine, Italy | Completed | No outcome recorded |
| Phase 3 | NCT01368588 | Jul 2011 → Apr 2025 overdue | prostate cancer | Radiation Therapy Oncology Group | Active not recruiting | Missed primary |
| Phase 3 | NCT01220869 | Dec 2010 → Oct 2012 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01242748 | Oct 2010 → Dec 2011 | prostate cancer | Ferring Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01215513 | Sep 2010 → Apr 2012 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01071915 | Mar 2010 → Nov 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00936390 | Sep 2009 → Oct 2020 | prostate cancer | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00884273 | Aug 2009 → Mar 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00967018 | Aug 2009 → Nov 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00946920 | Jun 2009 → Mar 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00928434 | May 2009 → Aug 2012 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00833248 | Apr 2009 → Sep 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00831233 | Apr 2009 → Jun 2010 | prostate cancer | Ferring Pharmaceuticals | Terminated | Met primary Stop: Enrollment |
| Phase 3 | NCT00801242 | Dec 2008 → Jun 2012 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00451958 | Mar 2007 → Oct 2011 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00295750 | Feb 2006 → Oct 2007 | prostate cancer | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00728533 | — | prostate cancer | Ferring Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT06001619 | Dec 2022 → Oct 2024 overdue | benign prostatic hyperplasia, prostate cancer | Turku University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05057546 | Nov 2021 → Sep 2024 overdue | — | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04248621 | Jan 2020 → Apr 2022 | prostate neoplasm | Wonju Severance Christian Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03202381 | Jun 2017 → Mar 2019 | prostate cancer | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Unknown | No outcome recorded |
| Phase 4 | NCT02726009 | May 2016 → May 2020 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02475057 | Aug 2015 → Jul 2018 | cardiovascular disorder, prostate cancer | Rabin Medical Center | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT03876912 | Mar 2019 → Sep 2021 | prostate cancer | Turku University Hospital | Unknown | No outcome recorded |
| — | NCT03313726 | Sep 2017 → Sep 2018 | prostate cancer | Turku University Hospital | Unknown | No outcome recorded |
| — | NCT01731912 | May 2013 → Sep 2016 | prostate adenocarcinoma | University of Washington | Completed | No outcome recorded |
| — | NCT01542021 | Feb 2012 → Sep 2024 | prostate adenocarcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT01344564 | Apr 2011 → Aug 2012 | prostate cancer | Urology of Virginia | Completed | No outcome recorded |
| Comparator or background therapy53 trials | ||||||
| Phase 0 | NCT07389187 Background | Feb → Dec 2026 expected | castration-resistant prostate carcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07389174 Background | Feb 2026 → Jan 2027 expected | prostate adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04301414 Comparator | Feb 2020 → Mar 2025 | prostate cancer | Columbia University | Completed | No outcome recorded |
| Phase 1 | NCT06531499 Background | Nov 2024 → Nov 2028 expected | prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06379217 Background | Jul 2024 → Sep 2026 overdue | prostate neuroendocrine neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05617885 Background | Aug 2023 → Jul 2025 | metastatic prostate carcinoma | Praful Ravi, MB BCHir, MRCP | Completed | No outcome recorded |
| Phase 1 | NCT02472275 Background | Jun 2015 → Aug 2019 | prostate adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01862835 Background | May 2013 → Sep 2016 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT04989946 Background | Dec 2021 → Dec 2026 expected | prostate cancer | University of Wisconsin, Madison | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04633252 Background | Feb 2021 → Dec 2026 expected | prostate cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03689699 Background | Oct 2018 → Sep 2023 overdue | prostate adenocarcinoma | Mark Stein | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07142551 Background | Mar 2026 → Jun 2030 expected | castration-resistant prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT07268794 Background | Nov 2025 → Apr 2027 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06922318 Background | Aug 2025 → Aug 2031 expected | castration-resistant prostate carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT05873192 Background | Jun 2025 → Dec 2026 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06528210 Background | Apr 2025 → Jun 2026 | prostate adenocarcinoma | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06734130 Background | Jan 2025 → Jan 2029 expected | metastatic prostate carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06378866 Comparator | Jun 2024 → Feb 2031 expected | castration-resistant prostate carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06059118 Background | Oct 2023 → Jan 2027 expected | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT05212857 Background | Apr 2022 → Feb 2024 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05189457 Background | Jan 2022 → Jul 2027 expected | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04734730 Background | May 2021 → Aug 2027 expected | prostate adenocarcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04126070 Background | May 2020 → Jul 2025 overdue | metastatic prostate carcinoma, prostate adenocarcinoma | Xiao X. Wei, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03951831 Background | May 2019 → Nov 2026 expected | metastatic prostate carcinoma | Mark Stein | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03899077 Comparator | Apr 2019 → Aug 2025 | prostate cancer | Cancer Research Antwerp | Unknown | No outcome recorded |
| Phase 2 | NCT03080116 Background | Mar 2019 → Jul 2021 overdue | prostate cancer | Universitaire Ziekenhuizen KU Leuven | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03311555 Background | Mar 2018 → Dec 2022 | prostate cancer | Andrew J. Armstrong, MD | Completed | No outcome recorded |
| Phase 2 | NCT02582749 Background | Apr 2016 → Sep 2017 | metastatic carcinoma in the bone, prostate cancer | Ajjai Alva, MD | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02278185 Comparator | Nov 2015 → Apr 2019 | prostate adenocarcinoma | University of Colorado, Denver | Completed | Missed primary |
| Phase 2 | NCT02560051 Comparator | Nov 2015 → Sep 2017 | prostate neoplasm | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01990196 Comparator | Sep 2014 → Sep 2024 overdue | prostate cancer | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02135445 Comparator | Jun 2014 → Dec 2015 | prostate cancer | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01786265 Background | Feb 2013 → Feb 2027 expected | prostate adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00116753 Comparator | Jan 2005 → Nov 2006 | prostate cancer | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT06282588 Background | Dec 2023 → Jul 2030 expected | prostate cancer | Cancer Research Antwerp | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04787744 Background | Jul 2021 → Sep 2026 overdue | metastatic prostate carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03070886 Background | Apr 2017 → Oct 2025 overdue | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07477626 Background | Mar 2026 → Dec 2033 expected | metastatic malignant neoplasm in the lymph nodes, prostate cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05050084 Background | Dec 2021 → Nov 2026 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04455750 Background | Oct 2021 → Mar 2027 expected | castration-resistant prostate carcinoma, prostate adenocarcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04513717 Background | Jan 2021 → Dec 2033 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04423211 Background | Oct 2020 → Dec 2032 expected | metastatic prostate carcinoma, prostate adenocarcinoma | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT03678025 Background | Sep 2018 → Apr 2033 expected | prostate adenocarcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT03009981 Background | Mar 2017 → Jun 2025 | prostate cancer | Alliance Foundation Trials, LLC. | Completed | Met primary |
| Phase 3 | NCT03240159 Comparator | Feb 2017 → Jun 2021 | ovarian ectopic pregnancy | Assisting Nature | Unknown | No outcome recorded |
| Phase 4 | NCT06264882 Background | Jun 2024 → May 2028 expected | — | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 4 | NCT01512472 Comparator | Jan 2012 → Jan 2018 | prostate cancer | Canadian Urology Research Consortium | Terminated | No outcome recorded |
| — | NCT07142967 Background | Aug 2025 → Aug 2028 expected | prostate cancer | NYU Langone Health | Recruiting | No outcome recorded |
| — | NCT05628363 Background | Jan 2023 → Oct 2025 overdue | prostate cancer | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| — | NCT04134130 Background | Sep → Dec 2019 | prostate cancer | Lund University | Completed | No outcome recorded |
| — | NCT02489357 Background | Dec 2015 → Nov 2017 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| — | NCT02478775 Background | Jul 2015 → Jun 2021 | infertility disorder, obesity disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT02346253 Background | Jan 2015 → Dec 2021 | prostate adenocarcinoma | Stanford University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-11-30 | Astellas Pharma Inc | Regulatory Astellas Submits a New Drug Application for Gonax® 12-Week Extended-Release Formulation for Treatment of Prostate Cancer in Japan astellas.com ↗
Astellas Submits a New Drug Application for Gonax® 12-Week Extended-Release Formulation for Treatment of Prostate Cancer in Japan |
| 2010-10-28 | Astellas Pharma Inc | Regulatory Astellas Pharma Inc.: Submits Application for Marketing Approval of Degarelix, an GnRH Antagonist for Prostate Cancer Treatment, in Japan astellas.com ↗
Tokyo, October 28, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it submitted a market authorization application for one month formulation of degarelix acetate (“degarelix”; generic name; development code: ASP3550) to the Ministry of Health, Labour and Welfare in Japan. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-11-30 | Astellas Pharma Inc | Astellas Submits a New Drug Application for Gonax® 12-Week Extended-Release Formulation for Treatment of Prostate Cancer in Japan astellas.com ↗ |
| 2010-10-28 | Astellas Pharma Inc | Astellas Pharma Inc.: Submits Application for Marketing Approval of Degarelix, an GnRH Antagonist for Prostate Cancer Treatment, in Japan astellas.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 147 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Degarelix | “All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 4-6 months, and luteinizing...” NCT01368588 ↗140“Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix...” NCT03311555 ↗ “Patients receive multitargeted tyrosine kinase inhibitor PLX3397 orally (PO) twice daily (BID) for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday)...” NCT02472275 ↗ “All subjects will receive androgen deprivation therapy with a LHRH agonist (any LHRH agonist such as leuprolide acetate or goserelin acetate is acceptable) or a LHRH antagonist...” NCT02582749 ↗ “This regimen consists of Androgen Deprivation Therapy (ADT) (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix) combined with an oral Androgen Receptor (AR) inhibitor...” NCT07389174 ↗ “Patients will continue on ADT with LHRH agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix) if not surgically castrated throughout...” NCT06922318 ↗ “For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months.” NCT04633252 ↗ “luteinizing hormone-releasing hormone (LHRH) agonist (i.e. Zoladex, Trelstar, Eligard, or Lupron) or LHRH antagonist (Degarelix or Relugolix)” NCT06059118 ↗ “ADT will be delivered with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.” NCT07801664 ↗ “Androgen deprivation therapy includes available GnRH agonists and antagonists, such as Triptorelin, Leuprolide, Goserelin and Degarelix.” NCT07477626 ↗ “The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.” NCT06001619 ↗ |
| Known as | Degarelix (as acetate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL415606 ↗ |
| Known as | Degarelix (Firmagon) | “Degarelix (Firmagon)” NCT03009981 ↗ |
| Known as | Degarelix accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL415606 ↗ |
| Known as | Degarelix acetate | “Gonadotropin releasing hormone (GnRH) antagonist is degarelix acetate, 80 mg, delivered once as a subcutaneous injection.” NCT05057546 ↗3“80-mg subcutaneous injection of degarelix acetate (20 mg/mL; Ferring Pharmaceuticals Inc, Parsippany, NJ)” NCT06264882 ↗ “Degarelix acetate, 1 mo depot for 3 months” NCT01344564 ↗ “Drug: degarelix acetate” NCT01696877 ↗ |
| Known as | Degarelix acetate hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL415606 ↗ |
| Known as | Degarelix acetate, FE200486 | “Degarelix acetate, FE200486” NCT00117286 ↗ |
| Known as | FE-200486 | ChEMBL registry synonym — accepted as the source's own label CHEMBL415606 ↗ |
| Known as | FE200486 (AS ACETATE SALT) | ChEMBL registry synonym — accepted as the source's own label CHEMBL415606 ↗ |
| Known as | FE200486 (FREE BASE) | ChEMBL registry synonym — accepted as the source's own label CHEMBL415606 ↗ |
| Known as | Firmagon | “Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix...” NCT03311555 ↗8“Study the effectiveness of the association of a short duration hormonal therapy by degarelix (Firmagon ®) and radiotherapy, with radiotherapy alone on survival without events...” NCT01994239 ↗ “Degarelix (Firmagon ®), a testosterone lowering agent given as a monthly injection, is FDA approved for the treatment of patients with advanced prostate cancer.” NCT01751451 ↗ “Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days” NCT03202381 ↗ “A 68Ga-PSMA-11 PET/MRI was performed once before and 3 times post-ADT (degarelix, Firmagon).” PMID 31879814 ↗ Dec 2019 “comparing 10 months versus 4 months of degarelix (Firmagon®) therapy” NCT01512472 ↗ “sub-cutaneous injection of GnRH-antagonist (Degarelix, Firmagon®)” NCT03876912 ↗ |
| Action | Inhibit | “Degarelix is a gonadotropin-releasing hormone receptor antagonist (blocker)” PMID 18801505 ↗ Sep 20081“Gonadotropin-releasing hormone receptor antagonist” CHEMBL415606 ↗ |
| Modality | Other / unclassified | “novel GnRH antagonist, degarelix” NCT00884273 ↗ |
| Route | Subcutaneous | “Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose” NCT00116753 ↗ |
| Target | GNRHR | “Gonadotropin-releasing hormone receptor antagonist” CHEMBL415606 ↗ |
| Target | TMPRSS2 | “suppress TMPRSS2” PMID 34225789 ↗ Jul 2021 |